共 50 条
Canadian Society of Nephrology Commentary on the 2012 KDIGO Clinical Practice Guideline for Glomerulonephritis: Management of Glomerulonephritis in Adults
被引:27
|作者:
Cybulsky, Andrey V.
[1
]
Walsh, Michael
[2
]
Knoll, Greg
[3
]
Hladunewich, Michelle
[4
]
Bargman, Joanne
[4
]
Reich, Heather
[4
]
Humar, Atul
[5
]
Samuel, Susan
[6
]
Bitzan, Martin
[7
]
Zappitelli, Michael
[7
]
Dart, Allison
[8
]
Mammen, Cherry
[9
]
Pinsk, Maury
[6
]
Muirhead, Norman
[10
]
机构:
[1] McGill Univ, Dept Med, Montreal, PQ, Canada
[2] McMaster Univ, Dept Med, Div Nephrol, Hamilton, ON, Canada
[3] Univ Ottawa, Dept Med, Div Nephrol, Ottawa, ON, Canada
[4] Univ Toronto, Dept Med, Toronto, ON, Canada
[5] Univ Alberta, Edmonton, AB, Canada
[6] Univ Alberta, Dept Pediat, Edmonton, AB, Canada
[7] Montreal Childrens Hosp, Montreal, PQ H3H 1P3, Canada
[8] Univ Manitoba, Dept Pediat & Child Hlth, Winnipeg, MB R3T 2N2, Canada
[9] Univ British Columbia, Dept Pediat, Vancouver, BC V6T 1W5, Canada
[10] Univ Western Ontario, Dept Med, Div Nephrol, London, ON N6A 5A5, Canada
关键词:
Clinical practice guideline implementation;
KDIGO (Kidney Disease: Improving Global Outcomes);
Canadian Society of Nephrology (CSN);
nephrotic syndrome;
glomerulonephritis;
ANTIBODY-ASSOCIATED VASCULITIS;
SYSTEMIC-LUPUS-ERYTHEMATOSUS;
TERM-FOLLOW-UP;
IDIOPATHIC MEMBRANOUS NEPHROPATHY;
CHRONIC KIDNEY-DISEASE;
DENSE DEPOSIT DISEASE;
IGA NEPHROPATHY;
LONG-TERM;
MYCOPHENOLATE-MOFETIL;
OXFORD CLASSIFICATION;
D O I:
10.1053/j.ajkd.2013.12.001
中图分类号:
R5 [内科学];
R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号:
1002 ;
100201 ;
摘要:
The KDIGO (Kidney Disease: Improving Global Outcomes) clinical practice guideline for management of glomerulonephritis was recently released. The Canadian Society of Nephrology convened a working group to review the recommendations and comment on their relevancy and applicability to the Canadian context. A subgroup of adult nephrologists reviewed the guideline statements for management of glomerular disease in adults and agreed with most of the guideline statements developed by KDIGO. This commentary highlights areas for which there is lack of evidence and areas in need of translation of evidence into clinical practice. Areas of controversy or uncertainty, including the choice of second-line agents, are discussed in more detail. Existing practice variation also is addressed. The relevance of treatment recommendations to the Canadian practitioner is discussed. (C) 2014 by the National Kidney Foundation, Inc.
引用
收藏
页码:363 / 377
页数:15
相关论文